Shanghai Jiaotong University Zhang Xueqing's research group develops a biomimetic nano-delivery system targeting brain tumors

Glioma is a primary malignant brain tumor.

Recently, Xueqing Zhang's research group from the School of Pharmacy, Shanghai Jiao Tong University officially published a research paper titled Targeted delivery of a STING agonist in brain tumor with enhanced immunotherapy using bioengineered protein nanoparticles in Bioactive Materials ( IF=14.

Research Introduction

The main challenge in the field of brain disease diagnosis and treatment is how to effectively make drugs break through the blood-brain barrier (BBB), while improving the targeting and permeability of the drug delivery system, so as to achieve efficient drug delivery to target tissues/cells

Then, the researchers used pH-mediated depolymerization-reassembly step to encapsulate the STING agonist SR717 into RGE-HFn nanocarriers to prepare SR717@RGE-HFn nanoparticles, and their morphology, physicochemical properties, and biological activities were obtained.

Summarize

Small molecule STING agonists have great application prospects in the field of tumor immunotherapy, but since STING is expressed in both tumors and normal tissues, intraperitoneal or intravenous injection of STING agonists can cause a systemic inflammatory storm; and its pharmacokinetics Poor in nature, STING agonists are all administered by intratumoral injection

Zhang Xueqing's group has developed a new biomimetic nano-delivery carrier with dual targeting functions for the first time, and used an in situ glioma mouse model to demonstrate that after intravenous injection, the biomimetic nano-carrier successfully crossed the BBB and carried STING agonist.

Zhang Xueqing from the School of Pharmacy, Shanghai Jiao Tong University is the corresponding author of the paper, and Wang Bin, a doctoral student from the School of Pharmacy, Shanghai Jiao Tong University, is the first author of the paper

Paper link : https:// class="Article-source form-horizontal">